Triumvira Immunologics, Inc.
NEWS
Employers have adjusted to higher salaries. That also means they’ve become adamant they get specific skill sets, according to Greg Clouse, BioSpace recruitment manager.
Triumvira Immunologics’ president and chief operating officer Rob Williamson noted that cell therapy companies might still have an uphill battle unless they can differentiate.
New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.
Most major money moves this week were related to immune therapy companies, including rounds of funding for T cell therapies, allergy therapies and immunomodulation platforms.
Triumvira’s inaugural program is directed against HER2, a well-known tumor-associated antigen that is expressed in multiple tumors.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
JOBS
IN THE PRESS